Hereditary Neoplastic Syndromes

Noralane Morey Lindor, Carl J. Lindor, Mark H. Greene

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The recent clinical availability of germ-line mutation testing for susceptibility genes related to the hereditary forms of common tumors such as breast, ovary, colorectum, and melanoma has served as a powerful catalyst for diverse research activities. Laboratory research, which has been propelled forward by access to carefully annotated biological samples obtained from cancer-prone families, is now challenged by an increasingly complex regulatory environment related to the ethical use of such specimens. Practitioners are being confronted by a host of new clinical issues, including those related to predictive risk assessment, genetic counseling, and germ-line mutation testing for clinical decision-making; the duty to warn at-risk relatives versus their high-risk patient's right to privacy and confidentiality; and, most importantly, the need for evidence-based, safe, and effective management recommendations for high-risk individuals. This chapter touches briefly upon some of these issues then provides a thumbnail description of selected hereditary cancer syndromes. It considers only some disorders for which a Mendelian mode of inheritance has been established and for which at least one germ-line susceptibility gene has been identified.

Original languageEnglish (US)
Title of host publicationCancer Epidemiology and Prevention
PublisherOxford University Press
ISBN (Print)9780199865062, 0195149610, 9780195149616
DOIs
StatePublished - Sep 1 2009

Fingerprint

Hereditary Neoplastic Syndromes
Germ-Line Mutation
Duty to Warn
Privacy
Confidentiality
Genetic Counseling
Touch
Patient Rights
Research
Germ Cells
Genes
Ovary
Melanoma
Neoplasms
Breast

Keywords

  • Cancer risk
  • Disease inheritance
  • Family history
  • Germ-line mutation
  • Susceptibility genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lindor, N. M., Lindor, C. J., & Greene, M. H. (2009). Hereditary Neoplastic Syndromes. In Cancer Epidemiology and Prevention Oxford University Press. https://doi.org/10.1093/acprof:oso/9780195149616.003.0028

Hereditary Neoplastic Syndromes. / Lindor, Noralane Morey; Lindor, Carl J.; Greene, Mark H.

Cancer Epidemiology and Prevention. Oxford University Press, 2009.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lindor, NM, Lindor, CJ & Greene, MH 2009, Hereditary Neoplastic Syndromes. in Cancer Epidemiology and Prevention. Oxford University Press. https://doi.org/10.1093/acprof:oso/9780195149616.003.0028
Lindor NM, Lindor CJ, Greene MH. Hereditary Neoplastic Syndromes. In Cancer Epidemiology and Prevention. Oxford University Press. 2009 https://doi.org/10.1093/acprof:oso/9780195149616.003.0028
Lindor, Noralane Morey ; Lindor, Carl J. ; Greene, Mark H. / Hereditary Neoplastic Syndromes. Cancer Epidemiology and Prevention. Oxford University Press, 2009.
@inbook{65c9d17db4bc40688b59fb345baed60a,
title = "Hereditary Neoplastic Syndromes",
abstract = "The recent clinical availability of germ-line mutation testing for susceptibility genes related to the hereditary forms of common tumors such as breast, ovary, colorectum, and melanoma has served as a powerful catalyst for diverse research activities. Laboratory research, which has been propelled forward by access to carefully annotated biological samples obtained from cancer-prone families, is now challenged by an increasingly complex regulatory environment related to the ethical use of such specimens. Practitioners are being confronted by a host of new clinical issues, including those related to predictive risk assessment, genetic counseling, and germ-line mutation testing for clinical decision-making; the duty to warn at-risk relatives versus their high-risk patient's right to privacy and confidentiality; and, most importantly, the need for evidence-based, safe, and effective management recommendations for high-risk individuals. This chapter touches briefly upon some of these issues then provides a thumbnail description of selected hereditary cancer syndromes. It considers only some disorders for which a Mendelian mode of inheritance has been established and for which at least one germ-line susceptibility gene has been identified.",
keywords = "Cancer risk, Disease inheritance, Family history, Germ-line mutation, Susceptibility genes",
author = "Lindor, {Noralane Morey} and Lindor, {Carl J.} and Greene, {Mark H.}",
year = "2009",
month = "9",
day = "1",
doi = "10.1093/acprof:oso/9780195149616.003.0028",
language = "English (US)",
isbn = "9780199865062",
booktitle = "Cancer Epidemiology and Prevention",
publisher = "Oxford University Press",

}

TY - CHAP

T1 - Hereditary Neoplastic Syndromes

AU - Lindor, Noralane Morey

AU - Lindor, Carl J.

AU - Greene, Mark H.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - The recent clinical availability of germ-line mutation testing for susceptibility genes related to the hereditary forms of common tumors such as breast, ovary, colorectum, and melanoma has served as a powerful catalyst for diverse research activities. Laboratory research, which has been propelled forward by access to carefully annotated biological samples obtained from cancer-prone families, is now challenged by an increasingly complex regulatory environment related to the ethical use of such specimens. Practitioners are being confronted by a host of new clinical issues, including those related to predictive risk assessment, genetic counseling, and germ-line mutation testing for clinical decision-making; the duty to warn at-risk relatives versus their high-risk patient's right to privacy and confidentiality; and, most importantly, the need for evidence-based, safe, and effective management recommendations for high-risk individuals. This chapter touches briefly upon some of these issues then provides a thumbnail description of selected hereditary cancer syndromes. It considers only some disorders for which a Mendelian mode of inheritance has been established and for which at least one germ-line susceptibility gene has been identified.

AB - The recent clinical availability of germ-line mutation testing for susceptibility genes related to the hereditary forms of common tumors such as breast, ovary, colorectum, and melanoma has served as a powerful catalyst for diverse research activities. Laboratory research, which has been propelled forward by access to carefully annotated biological samples obtained from cancer-prone families, is now challenged by an increasingly complex regulatory environment related to the ethical use of such specimens. Practitioners are being confronted by a host of new clinical issues, including those related to predictive risk assessment, genetic counseling, and germ-line mutation testing for clinical decision-making; the duty to warn at-risk relatives versus their high-risk patient's right to privacy and confidentiality; and, most importantly, the need for evidence-based, safe, and effective management recommendations for high-risk individuals. This chapter touches briefly upon some of these issues then provides a thumbnail description of selected hereditary cancer syndromes. It considers only some disorders for which a Mendelian mode of inheritance has been established and for which at least one germ-line susceptibility gene has been identified.

KW - Cancer risk

KW - Disease inheritance

KW - Family history

KW - Germ-line mutation

KW - Susceptibility genes

UR - http://www.scopus.com/inward/record.url?scp=84920422948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920422948&partnerID=8YFLogxK

U2 - 10.1093/acprof:oso/9780195149616.003.0028

DO - 10.1093/acprof:oso/9780195149616.003.0028

M3 - Chapter

AN - SCOPUS:84920422948

SN - 9780199865062

SN - 0195149610

SN - 9780195149616

BT - Cancer Epidemiology and Prevention

PB - Oxford University Press

ER -